Breaking the barrier

A three-way deal between Amgen Inc., Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics.

The biotechs join a small but growing cohort of companies creating protein-based therapeutics that can cross the plasma membrane to reach intracellular targets - a challenge that has plagued the field almost since the dawn of the industry...